Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. by Johns, LE et al.
Effect of population breast screening
on breast cancer mortality up to 2005
in England and Wales: an individual-level
cohort study
Louise E Johns*,1, Derek A Coleman1, Anthony J Swerdlow1,2 and Susan M Moss3
1Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK; 2Division of Breast Cancer
Research, The Institute of Cancer Research, London SW3 6JB, UK and 3Centre for Cancer Prevention, Wolfson Institute of
Preventative Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
Background: Population breast screening has been implemented in the UK for over 25 years, but the size of benefit attributable to
such programmes remains controversial. We have conducted the first individual-based cohort evaluation of population breast
screening in the UK, to estimate the impact of the NHS breast screening programme (NHSBSP) on breast cancer mortality.
Methods: We followed 988 090 women aged 49–64 years in 1991 resident in England and Wales, who because of the staggered
implementation of the NHSBSP, included both invited subjects and an uninvited control group. Individual-level breast screening
histories were linked to individual-level mortality and breast cancer incidence data from national registers. Risk of death from
breast cancer was investigated by incidence-based mortality analyses in relation to intention to screen and first round attendance.
Overdiagnosis of breast cancer following a single screening round was also investigated.
Results: Invitation to NHSBSP screening was associated with a reduction in breast cancer mortality in 1991–2005 of 21% (RR¼ 0.79,
95% CI: 0.73–0.84, Po0  001) after adjustment for age, socioeconomic status and lead-time. Breast cancer deaths among first
invitation attenders were 46% lower than among non-attenders (RR¼ 0.54, 95% CI: 0.51–0  57, Po0.001) and 32% lower following
adjustment for age, socioeconomic status and self-selection bias (RR¼ 0.68, 95% CI: 0.63–0  73, Po0.001). There was little
evidence of overdiagnosis associated with invitation to first screen.
Conclusions: The results indicate a substantial, statistically significant reduction in breast cancer mortality between 1991 and 2005
associated with NHSBSP activity. This is important in public health terms.
Population breast screening was introduced in a number of
countries from the late 1980s after randomised controlled trials
reported that mammographic screening could reduce breast cancer
mortality by an average of 23% in invited women aged 50–69 years
(Lauby-Secretan et al, 2015). Debate, however, continues about the
relative benefits and disadvantages of such screening programmes
(Paci et al, 2014; Bleyer et al, 2016; Jorgensen and Gotzsche, 2016).
This, coupled with ongoing improvements in breast cancer
treatment, has led to questions about the value of population
screening in reducing breast cancer mortality, and highlighted the
need to evaluate the effectiveness of existing population breast
screening programmes.
With the exception of Finland, population-based breast screen-
ing has been introduced without intrinsic provision for evaluation,
making identification of an uninvited comparison population
difficult. The use of individual-level data to take into account the
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screening history of each woman and to identify breast cancers
diagnosed before invitation has been strongly recommended
(Broeders et al, 2012; Weedon-Fekjaer et al, 2014). However, such
data are not readily available and relatively few evaluation studies
have used individual screening and outcome data.
The UK NHS Breast Screening Programme (NHSBSP) is one of
the largest nationally organised programmes in the world,
currently inviting nearly three million women each year (Health
and Social Care Information Centre, 2016). The NHSBSP was
introduced in 1988 inviting women aged 50–64 years every 3 years.
Implementation of the NHSBSP was gradual, with the first
screening round not completed until 1995.
To evaluate the impact of the NHSBSP in England and Wales
on breast cancer mortality we conducted a retrospective cohort
analysis using individual-level screening exposure and mortality
outcome data. The staggered implementation period of the
programme was used to provide an uninvited control group. This
paper presents an analysis of the impact of NHSBSP activity on
breast cancer mortality between 1991 and 2005.
MATERIALS AND METHODS
We describe our methods briefly below, with additional details
provided in Supplementary Material.
Subjects and data acquisition. The study area covered around
one third of England and the whole of Wales (Supplementary
Figure A), designed to include the earliest and latest areas to begin
NHS screening. The cohort were women aged 49–64 years,
resident in the study area and free from breast cancer on 1 January
1991. Breast screening histories were extracted from screening call/
recall databases in the study area. Personal details were augmented
using data from the NHS Strategic Tracing Service (NSTS; now the
Demographics Batch Service, part of the NHS Care Records
Service) to aid linkage between different sources of the data. Dates
of death were obtained from screening call/recall databases, the
NSTS, and the Office for National Statistics (ONS). Data on
underlying cause of death were collected from ONS and breast
cancer deaths were those for which breast cancer was coded as the
underlying cause. Data on incidence of breast cancer, including
in situ disease, were collected from the national cancer registration
system. Socioeconomic status (SES) was estimated based on
postcode of residence at study entry using the Townsend Index
(Phillimore et al, 1994) based on data from the 1991 census
(Supplementary Materials 1, 2 and 3).
Data collection from ONS was accomplished by individual-level
electronic record linkage to the screening data. The NHSBSP in
England andWales started in 1988, but data on cause of death collected
by linkage for 1988–1990 were incomplete and therefore analyses for
this study started in 1991 (Supplementary Material 5). The analysis
population for this study is shown in the lexis diagram, Figure 1. Data
linkage was complex and time-consuming and was accomplished to the
end of 2005. Follow-up ended at 31st December 2005.
The study protocol was approved by the Department of Health
for England, ethics approval was obtained from the South East
MREC (MREC 02/01/64) and exemption from individual informed
consent was approved by the then Patient Information Advisory
Group (PIAG 3-07(g)/2002).
Analyses. Women entered the study on 1 January 1991 and exited at
date of death, date lost to follow-up or 31 December 2005, whichever
was earliest (Supplementary Material 4). Primary analysis was
conducted on an ‘intention-to-screen’ basis (i.e., ‘exposed’ women
were those invited for screening, not just those who attended). In the
NHSBSP, women were scheduled for invitation on the basis of
demographic information and their further eligibility was checked by
their GP practice before being invited. This process of checking
suitability for screening with GPs on the basis of health status (a
process that has now ceased) meant that ill-health could result in a
scheduled woman not being invited at that episode. Under these
circumstances, use of invitation as the measure of exposure in an
intention to screen analysis could have led to an estimate that was
biased in favour of screening because of a healthy invitee effect
(Supplementary Material 6). To avoid healthy invitee bias, we
therefore used scheduling for invitation as the measure of exposure in
our intention-to-screen analyses (referred to below simply as
‘invitation’). To reflect the potential for women to move between
exposure groups over time, the intention-to-screen analysis of
mortality used incidence-based mortality (IBM), in which deaths
from breast cancer were assigned to the woman’s exposure group at
diagnosis (Njor et al, 2012). This excludes deaths in breast cancer
diagnosed before the start of the study period, and ensures that a
woman who dies after invitation to breast screening from a breast
cancer diagnosed before invitation is counted as a death in the
unexposed group. The analysis was designed to ensure that women
with breast cancer had the same length of follow-up in both the
exposed and unexposed groups. The 15-year period 1991–2005 was
partitioned into observation periods that were of equal length in both
the invited and uninvited groups. Each observation period included
an initial period of 2 years during which breast cancer cases and
person-years were accrued, and extended up to 9 years, measured
from the start of the observation period, to follow-up for death in any
of these breast cancers. As most women were invited for screening
relatively soon after the start of the study, this allowed for one
observation period in the unexposed group and up to three
observation periods in the exposed group. The strict partitioning of
time in this analysis resulted in the inclusion of screening activity up
to year 2000. Full details of the IBM analysis methodology are
described in the Supplementary Material 7.
Lead-time bias consequent on screening advancing the date of
diagnosis can bias results against a positive effect of screening in
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Figure 1. Study population and women available for analysis.
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IBM analysis by including breast cancer deaths in women who
would otherwise have been diagnosed beyond the accrual period
(Njor et al, 2012). Intention-to-screen analyses were adjusted for
this bias (Supplementary Material 8) assuming a lead-time of 3
years for screen-detected cases (Supplementary Material 3), based
on published estimates of lead-time (Weedon-Fekjaer et al, 2005;
Svendsen et al, 2006). Analyses were repeated using lead-time
estimates of one, 5 and 7 years.
A conventional mortality analysis of intention to screen was also
conducted in which deaths were allocated to exposure groups at
the date of death and breast cancer mortality in women living in
the earliest and latest areas to start screening was compared. We
designated as early-starting postcode districts those where X95%
of women were first invited before December 1991 and late-
starting areas where X95% of women were first invited after July
1993. Follow-up continued until the end of 2005.
We conducted an analysis based on screening attendance,
dividing women at entry according to whether or not they had
attended within 6 months of their first screening invitation. In the
NHSBSP, if a woman does not attend within 6 months of her
invitation, the episode is closed. The limit of 6 months therefore
ensures that in our analysis any attendance relates directly to the
correct invitation. In this analysis, only women who had been sent
an invitation were included. Estimates were adjusted to take
account of the increased mortality risk in women who do not
accept screening (self-selection bias; Duffy and Cuzick, 2002),
using information on uninvited women from the cohort to derive a
population-specific correction factor (Supplementary Material 9).
To investigate overdiagnosis of breast cancer due to screening, a
cumulative incidence analysis (Biesheuvel et al, 2007) of invasive
and in situ breast cancers diagnosed in women with the earliest
birth years in the cohort (1927–1929) was conducted. Some of
these women, due to their age and the staggered introduction of
screening, were never invited by the NHSBSP. Those who were
invited would have had only a single invitation (women were not
invited above age 64 years at that time), giving at least 12 years of
follow-up for lead-time to dissipate so that any remaining excess
incidence in the invited group can be attributed to screening.
Excess incidence has been expressed both as a proportion of
observed incidence in uninvited women and of that in invited
women, methods A and B advocated by the Independent UK Panel
on Breast Cancer Screening (2012); Supplementary Material 10.
Standardised mortality rates (SMRs; i.e., mortality rates in the
cohort compared with national rates), adjusted by age and calendar
year were used to compare non-breast cancer mortality between
exposure groups (Supplementary Material 11).
The number of women needed to be invited to save one breast
cancer death was calculated as the reciprocal of the number of lives
saved per woman invited (Supplementary Material 12). The
number needed to be screened to save one breast cancer death
was calculated according to the method of Richardson, (2001)
(Supplementary Material 13).
Poisson regression, conducted in STATA V10  0 (StataCorp,
College Station, TX, USA), was used to calculate rate ratios and
associated 95% confidence intervals and P-values. Age and
socioeconomic status were included as covariates in the model.
RESULTS
Data on a total of 1 426 379 women aged 49–64 years on 1 January
1991 were extracted from 28 screening call/recall databases. Of
these, we excluded from analyses women who were not traced at
NSTS (14 157), women with breast cancer diagnosed before 1
January 1991 (28 870) and women invited before 1 January 1991
(395 262). This resulted in an analysis population of 988 090
women.
Between 1 January 1991 and 31 December 2005, there were
41 120 cases of breast cancer diagnosed and 146 539 deaths in the
cohort, including 8002 deaths from breast cancer. Linkage failed
to produce an underlying cause of death for 2% of deaths
(3032/146 539). To determine whether any of the missing causes of
death were due to breast cancer, all women whom we knew from
cancer registration had been diagnosed with breast cancer but
whose cause of death was not known (n¼ 101) were flagged at the
NHS central register to determine an underlying cause. None was
found to have died of breast cancer. A total of 39 134 women (4%)
were lost to follow-up for reasons other than death before 31
December 2005, and a further 8014 who left the study area before
being scheduled for NHSBSP invitation were lost to follow-up in
the IBM analysis.
Intention-to-screen analyses
Breast cancer incidence-based mortality in invited compared
with uninvited women. Breast cancer mortality was 17% lower in
women invited for screening than in uninvited women (RR¼ 0.83,
95% CI: 0.78–0.89, Po0.001; Table 1), and the estimate was
similar following adjustment for age and SES (RR¼ 0.82, 95% CI:
0.76–0.88, Po0.001). After adjusting for lead-time bias of 3 years,
the mortality reduction increased to 21% (RR¼ 0.79, 95% CI:
0.73–0.84, Po0.001). The absolute difference was 0.31 per 1000
person-years and the number needed to be invited to save one
Table 1. Breast cancer mortality in invited compared with uninvited women
Rate ratio (95% CI, P-value)
Exposure
status
Number
of women
Number of
person-years
Number
of breast
cancer
deaths
Crude breast
cancer mortality
rate per 1000
person-years
Crude
Adjusted for age and
socioeconomic
statusa
Adjusted for age,
socioeconomic status
and lead-timeb
Incidence-based mortality
Not invited
988 090
1675 356 1239 0.74 1.00 1.00 1.00
Invited 4719 228 2912 0.62 0.83 (0.78–0.89, o0.001) 0.82 (0.76–0.88, o0.001) 0.79 (0.73–0.84, o0.001)
Late- and early-starting screening areas
Late-starting 52 949 723 558 490 0.68 1.00 1.00 n/ac
Early-starting 49 713 685 758 373 0.54 0.80 (0.70–0.92, 0.001) 0.82 (0.71–0.94, 0.004) n/ac
Abbreviation: CI¼ confidence interval.
aAdjusted for single year of age and socioeconomic status quintile.
bAdjusted for lead-time of 3 years.
cLead-time does not affect this analysis.
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death from breast cancer was 1436 (based on inviting women for
2 years and 9 years of follow-up). Non-breast cancer SMRs in the
invited and uninvited groups were 0.96 (0.95–0.97) and 0.98 (0.96–
1.00), respectively, SMR ratio 0.98.
Breast cancer mortality in early- compared with late-starting
screening areas. Early- and late-starting areas had populations of
49 713 and 52 949 study women, respectively. Mean follow-up in
this analysis was 13.7 years. Adjusted for age and SES, breast
cancer mortality in the early-starting areas was 18% lower than in
the late-starting areas (RR¼ 0.82, 95% CI: 0.71–0  94, P¼ 0.004;
Table 1).
Breast cancer mortality in screening attenders compared with
non-attenders. A total of 790 946 women were invited to their
first screen between ages 49 and 64 years, and 587 809 (74%)
attended within 6 months. The breast cancer mortality reduction in
women who attended their first screen compared with those who
did not attend was 46% (RR¼ 0  54, 95% CI: 0.51–0.57, Po0.001)
and this estimate was unaffected when adjusted for age and SES
(Table 2). The absolute difference was 0.50 per 1000 person-years
and the number needed to be screened in order to save one death
from breast cancer was 1020 (where screened women attended a
first screen within 6 months of invitation and attended on average
2.8 screens over a mean 12.3 years follow-up). After adjustment for
self-selection bias, using the population-specific correction factor
of 1.19, the mortality reduction was 32% (RR¼ 0  68, 95% CI:
0.63–0.73, Po0.001).
Analyses of overdiagnosis of breast cancer. A total of 162 502
women aged 62–64 years at entry contributed 2 033 325 person-
years of follow-up during which 6108 breast cancers were
diagnosed. Lead-time effects were apparent when follow-up was
censored at the end of 1995 or the end of 2000, but had
disappeared by 2005. At the end of follow-up, the cumulative
incidence rates of breast cancer adjusted for SES in the invited and
uninvited groups were 3.01 (95% CI: 2.89–3.13) and 3.00 (95% CI:
2.90–3.10) cases per 1000 person-years, respectively (P¼ 0.90 for a
difference between groups). This equates to 0.3% overdiagnosis
after one invitation and 12 years of follow-up as a percentage of the
observed incidence in either invited or uninvited women.
DISCUSSION
This is the first cohort study using individual-level data to evaluate
NHS breast screening in the UK, and worldwide it is one of the
largest IBM evaluations of population breast screening that has
been conducted. Our findings suggest that breast cancer mortality
was 21% lower in women invited by the NHSBSP between 1991
and 2000 compared with women of the same age who were not
invited. Among women invited for their first screen, breast cancer
mortality was 32% lower in attenders than non-attenders, adjusted
for self-selection bias.
Previously published studies specifically reporting the impact of
the UK breast screening programme on breast cancer mortality
have either relied on modelling aggregated data (Blanks et al, 2000;
Duffy et al, 2010) or have used a case-control approach based on
individual-level data (Fielder et al, 2004; Allgood et al, 2008;
Massat et al, 2016).
Our results are similar to those from a recent review and meta-
analysis of the impact of mammographic screening on breast
cancer mortality in Europe published in 2012 for the EURO-
SCREEN Working Group (Broeders et al, 2012). The reviewers
identified seven eligible IBM studies, where mortality rates were
calculated on the basis of breast cancer deaths occurring in women
with breast cancer diagnosed after their first invitation to
screening. The reported pooled breast cancer mortality reduction
was 25% (RR 0.75, 95% CI: 0.69–0.81) among invited women and
38% among those screened (RR 0.62, 95% CI: 0.56–0.69).
Since this European review, two additional large IBM evalua-
tions of organised breast screening in Norway and Finland have
been published (Weedon-Fekjaer et al, 2014; Parvinen et al, 2015).
These studies reported reductions in death from breast cancer of
between 25 and 28% associated with invitation to screening. Our
UK evaluation is very similar in design to the study in Norway,
where screening was implemented gradually between 1995 and
2005. The Norwegian study found a 28% reduction in breast cancer
mortality among women invited (RR¼ 0.72, 95% CI: 0.64–0.79)
and a 37% reduction associated with screening attendance
(Weedon-Fekjaer et al, 2014). The greater magnitude of mortality
reduction in Norway compared with our UK study might be
accounted for by a more recent screening period employing
contemporary screening practice, a shorter screening interval
(2 years in Norway, 3 years in the UK) and the use of two-view
mammography at all screens throughout the Norwegian evaluation
period compared with two-views at the first screen only in most of
the NHSBSP during the study period.
Analysis of early vs late start of screening. The comparison of
mortality in early- and late-starting screening areas showed
a relative reduction in breast cancer mortality of 18% in early-
starting areas. This is likely to be due to women in the
early-starting areas receiving screening over a longer period of
time. Although this was a logical evaluation approach, it was
subject to dilution by subsequent screening in late-starting areas.
Nevertheless, the observed breast cancer mortality reduction of
18% was consistent with the 21% reduction estimated by the more
rigorous intention-to-screen IBM approach, albeit with wider
confidence intervals.
Overdiagnosis. As a consequence of breast screening, some early-
stage tumours are diagnosed which would never progress to
become clinically apparent during a woman’s lifetime. This
represents overdiagnosis. Whilst our study was primarily designed
Table 2. Breast cancer mortality (conventional) in attenders and non-attenders in response to first round screening invitation:
women aged 49–64 years at invitation
Rate ratio (95% CI, P-value)
Exposure
status
Number
of women
Number of
person-years
Number
of breast
cancer
deaths
Rate per 1000
person-years Unadjusted
Adjusted for age
and socioeconomic
statusa
Adjusted for age,
socioeconomic status
and selection biasb
Attenders 587 809 7411762 3120 0.42 0.54 (0.51–0.57, o0.001) 0.54 (0.51–0.57, o0.001) 0.68 (0.63–0.73, o0.001)
Non-attenders 203 137 2347909 1845 0.79 1.00 1  00 1.00
Abbreviation: CI¼ confidence interval.
aAdjusted for single year of age and socioeconomic status quintile.
bAdjusted for self-selection bias using non-attender to uninvited breast cancer mortality ratio.
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to estimate the impact of NHS breast screening on breast cancer
mortality, the oldest birth cohorts offered an opportunity to
investigate overdiagnosis of breast cancer in relation to screening
activity. By 2005, lead-time effects in the invited group had
dissipated, so that unlike previously published estimates of
overdiagnosis in the NHSBSP (Wilson and Evans, 2006; Duffy
et al, 2010; Jorgensen and Gotzsche, 2010), our analysis indicated
only 0.3% overdiagnosis associated with invitation. This increased
to 0.5% if expressed as a percentage of cases diagnosed in the first 7
years. Our finding of so little overdiagnosis may be due to our
analysis being based predominantly on one invitation per woman,
whereas previously published estimates of around 10–15% over-
diagnosis in the NHSBSP and elsewhere are based on screening
histories including multiple attendances per woman (Duffy and
Parmar, 2013; Michalopoulos and Duffy, 2016). A cohort study in
Italy used the cumulative incidence method to investigate
overdiagnosis in women aged 60–69 years at entry in the first
round of the Florentine screening program. After 5–14 years
follow-up, they found 5% overdiagnosis of invasive breast cancer
alone and 10% overdiagnosis of invasive plus in situ breast cancer
(1.10 (0.98–1.23); Puliti et al, 2012). Our estimate of overdiagnosis
increases to 5% if follow-up is restricted to 7 years; however, this is
less than the follow-up recommended (Independent UK Panel on
Breast Cancer Screening, 2012), and the risk of overestimating
overdiagnosis if follow-up is too short has been demonstrated
(Duffy and Parmar, 2013).
Strengths and limitations of our analysis. This study uses
individual-level data for both screening and outcome data. The
failure to accurately measure exposure to screening and to adopt an
incidence-based mortality approach is a key limitation of studies
that have examined population trends for the purpose of evaluating
breast screening (Moss et al, 2012). Our IBM analyses were
restricted to women free from breast cancer at entry to avoid
dilution of the effect of screening; 57% of breast cancer deaths
occurring between 1991 and 2000 were diagnosed before 1991,
similar to proportions reported by others (Hakama et al, 1999;
Duffy et al, 2002). The study was, however, potentially subject to a
range of biases. Healthy invitee bias was minimised by using
scheduling for invitation rather than invitation for screening as the
measure of exposure in intention-to-screen analyses. Pro-screening
lead-time bias that arises when follow-up is measured from the
date of breast cancer diagnosis was avoided in our study by
measuring follow-up from the start of observation. Incidence-
based mortality analyses were adjusted for the form of lead-time
bias that acts against screening in this type of analysis (Njor et al,
2012). Varying the lead-time estimate used in the adjustment to 1,
5 and 7 years resulted in estimated breast cancer mortality
reductions of 17, 22 and 26%, respectively.
We were unable to ascertain dates of breast cancer diagnosis for
5% of breast cancer deaths. Sensitivity analyses excluding such
cases had no impact on the estimates of the effect of screening on
mortality. Findings were also unaffected when analyses were
conducted excluding the 2% of deaths with unknown cause.
Findings from analyses comparing mortality in screening
attenders with that in non-attenders are highly dependent on the
magnitude of the correction factor used to adjust for self-selection
bias. We applied a population-specific correction factor of 1.19,
derived from the UK cohort study data, that was similar in
magnitude to the correction factors 1.11 and 1.17 derived from
Italian and Icelandic evaluation study data, respectively (Gabe et al,
2007; Puliti et al, 2008). An alternative analysis, using the
correction factor of 1.36 derived from Swedish and Canadian
trials (Duffy and Cuzick, 2002) resulted in a reduction of 17%.
However, uptake of screening in those trials was high compared
with the UK and applying a trial-derived correction to UK
population screening may overcorrect (Paap et al, 2011).
Application of a correction factor of 0.95, derived from a recent
case–control evaluation of the NHSBSP (Massat et al, 2016) would
increase estimated breast cancer mortality reduction amongst
attenders for screening in our study to 50%.
There were concerns that screening exposure data collected
from the breast screening call/recall system might not accurately
reflect screening prior to 1995. Validation by checking detailed
screening histories of over 100 000 individuals indicated a high
level of accuracy and completeness overall, but there was evidence
of some missing screening information in some areas before 1995.
The effect of this would be to dilute a positive effect of screening.
Temporal differences between exposure groups in our intention
to screen IBM analyses mean they are potentially confounded by
changes in non-screening factors over time. Falling UK breast
cancer mortality rates since 1990 are likely to be due to a
combination of factors, including improvements in treatment and
the direct effect of screening through earlier detection and
treatment. In addition, there are likely to be indirect screening
effects which include increased breast awareness associated with
promotion of the NHSBSP (Stockton et al, 1997) and better access
to multi-disciplinary breast care (Department of Health and Welsh
Office, 1995; Kalager et al, 2010). Although we have identified a
reduction in breast cancer mortality associated with NHSBSP
screening, we were not able to differentiate the contribution made
by the direct and indirect effects of screening. Temporal differences
between exposure groups in our intention-to-screen IBM analyses
mean they are potentially confounded by changes in non-screening
factors over time. However, these temporal differences were
relatively small, thus minimising the likelihood of confounding
due to changes in non-screening factors. Furthermore, use of
Tamoxifen and adjuvant therapy was widespread during the period
covered by this evaluation (Alexander et al, 1994; Moritz et al,
1997; Swerdlow and Jones, 2005) so that changes in these factors
are unlikely to have substantially affected the results.
Findings from this large evaluation of the NHSBSP are similar
to those reported by cohort evaluations of organised screening in
other countries (Jonsson et al, 2001; Paci et al, 2002; Olsen et al,
2005; Swedish Organised Service Screening Evaluation Group,
2006; Weedon-Fekjaer et al, 2014; Parvinen et al, 2015). Our
analyses primarily cover NHSBSP activity up to 2000; changes
since 2000 have included the introduction of two-view mammo-
graphy at all screens, which has increased the sensitivity of
screening (Blanks et al, 2005), but may also have led to an increase
in recall rate and/or overdiagnosis.
CONCLUSIONS
The wide variety of approaches that have been used to estimate the
impact of population breast screening reflects the difficulty of
evaluating programmes that were introduced without provision of
a suitable comparison population. Cohort studies using individual-
level data and observed mortality represent a robust approach to
evaluation and this study is the first evaluation of the NHS breast
screening programme to adopt such a strategy. This cohort study
adds considerably to the body of evidence indicating that
population-based mammographic screening leads to a reduction
in breast cancer mortality.
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